Date published: 2025-10-15

1-800-457-3801

SCBT Portrait Logo
Seach Input

GGH Inhibitors

GGH inhibitors, or gamma-glutamyl hydrolase inhibitors, belong to a specific chemical class of compounds that play a crucial role in the regulation of the gamma-glutamyl cycle, which is a critical component of amino acid metabolism. These inhibitors are designed to target the enzyme gamma-glutamyl hydrolase, abbreviated as GGH, which is primarily responsible for catalyzing the hydrolysis of gamma-glutamyl compounds. The gamma-glutamyl cycle is a fundamental biochemical pathway involved in the synthesis and degradation of glutathione, a potent antioxidant found in cells throughout the body. GGH inhibitors disrupt this cycle by inhibiting the enzymatic activity of GGH, thereby influencing the levels of gamma-glutamyl compounds and, consequently, altering glutathione metabolism.

Structurally, GGH inhibitors encompass a diverse range of compounds, including small molecules and peptides, each designed to interact with the active site of the GGH enzyme, inhibiting its ability to break down gamma-glutamyl compounds. This interference with GGH's enzymatic activity has far-reaching implications for cellular redox balance, as glutathione is a key player in protecting cells from oxidative damage and maintaining intracellular homeostasis. GGH inhibitors are important tools for researchers studying the complex interplay between glutathione metabolism and various physiological processes.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$25.00
$117.00
$209.00
27
(1)

Inhibits tyrosine kinase activity of BCR-ABL and c-KIT, disrupting signaling pathways in cancer cells.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$56.00
$260.00
$416.00
129
(3)

Blocks RAF/MEK/ERK and VEGF receptor signaling, inhibiting angiogenesis and tumor cell proliferation.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$62.00
$112.00
$214.00
$342.00
74
(2)

Selectively inhibits epidermal growth factor receptor (EGFR) tyrosine kinase, impeding tumor growth and progression.

Erlotinib Hydrochloride

183319-69-9sc-202154
sc-202154A
10 mg
25 mg
$74.00
$119.00
33
(1)

Targets EGFR kinase, preventing autophosphorylation and downstream signaling, hindering cancer cell proliferation.

Lapatinib

231277-92-2sc-353658
100 mg
$412.00
32
(1)

Dual inhibition of EGFR and HER2 kinases, hindering their signaling pathways in breast cancer cells.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$47.00
$145.00
51
(1)

Binds to multiple tyrosine kinases, including BCR-ABL, blocking downstream signaling and inhibiting leukemia cells.

Vemurafenib

918504-65-1sc-364643
sc-364643A
10 mg
50 mg
$115.00
$415.00
11
(1)

Selective inhibition of mutant BRAF kinase, impairing MAPK signaling and inhibiting melanoma cell growth.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$150.00
$920.00
5
(0)

Inhibits multiple receptor tyrosine kinases, including VEGFR and PDGFR, hampering tumor angiogenesis and growth.

Nilotinib

641571-10-0sc-202245
sc-202245A
10 mg
25 mg
$205.00
$405.00
9
(1)

Potent BCR-ABL inhibitor, suppressing tyrosine kinase activity.

Pazopanib

444731-52-6sc-396318
sc-396318A
25 mg
50 mg
$127.00
$178.00
2
(1)

Targets VEGFR, PDGFR, and c-KIT kinases, inhibiting angiogenesis and stalling tumor progression.